Jeffrey Rado, MD
Psychiatry · Chicago, ILNPI 1881706455
Payments from drug & device makers
Across 542 payments — averaging $2245.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$333K
- Hoffmann-la Roche Limited$226K
- Acadia Pharmaceuticals Inc$146K
- E.r. Squibb & Sons, L.L.C.$138K
- Biogen$125K
- Janssen Research & Development, LLC$68K
- plus $182K from 13 others
Across 1 payment — averaging $2200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$57,26028%
- Speaking & faculty fees$135,27265%
- Travel & lodging$8,9084%
- Food & beverage$6,4823%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 257 | $333,074 |
| Hoffmann-la Roche Limited | 34 | $225,707 |
| Acadia Pharmaceuticals Inc | 86 | $146,041 |
| E.r. Squibb & Sons, L.L.C. | 35 | $137,580 |
| Biogen | 3 | $124,901 |
| Janssen Research & Development, LLC | 6 | $67,877 |
| Teva Pharmaceuticals USA, Inc. | 45 | $55,611 |
| AbbVie | 5 | $51,123 |
| Boehringer Ingelheim | 8 | $21,345 |
| Axsome Therapeutics, Inc. | 26 | $19,942 |
| Boehringer Ingelheim International GmbH | 7 | $8,800 |
| Janssen Global Services, LLC | 9 | $7,903 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $4,542 |
| H. Lundbeck A S | 5 | $3,844 |
| Boehringer Ingelheim RCV GmbH & Co KG | 5 | $3,178 |
| Noven Pharmaceuticals, Inc. | 3 | $2,390 |
| Indivior Inc. | 1 | $1,788 |
| Janssen Scientific Affairs, LLC | 1 | $1,450 |
| Sage Therapeutics, LLC | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$303,064
- ARISTADA$159,882
- ARISTADA INITIO$39,750
- Auvelity$19,519
- COBENFY$11,314
- SPRAVATO$5,526
- CAPLYTA$4,500
- ABILIFY MAINTENA$3,765
- SECUADO$2,390
- PERSERIS$1,788
How this compares
$1,217,217 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 17 | $58,735 |
| Clozapine | 76 | $10,707 |
| Divalproex Sodium ErDivalproex Sodium | 36 | $6,653 |
| BelsomraSuvorexant | 13 | $6,584 |
| Quetiapine Fumarate | 117 | $1,849 |
| Olanzapine | 70 | $1,762 |
| Aripiprazole | 47 | $1,628 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,613 |
| Bupropion XlBupropion Hcl | 74 | $1,613 |
| Duloxetine Hcl | 72 | $1,561 |
| Ziprasidone Hcl | 12 | $1,080 |
| Fluoxetine Hcl | 61 | $933 |
| Gabapentin | 45 | $827 |
| Lamotrigine | 75 | $789 |
| Trazodone Hcl | 57 | $575 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Chicago
- Yuhwen ChowChicago$8.5M
- Jon GrantChicago$1.4M
- Mitchell GlaserChicago$1.1M
- Peter WeidenChicago$941K
- Brett PlylerChicago$293K
- Michelle DeesChicago$289K
- Jennifer SpragueChicago$288K
- K Ranga KrishnanChicago$92K
- Pawel DudekChicago$52K
- Richard BaerChicago$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.